ATENT & TRIBE

JC17 Rec'd PCT/PTO 1 6 APR 2001 PCT

Filed Via Certified Mail

Rec. No.: 7000 0600 0024 0744 4329

April 13, 2001

and Schoonles

Any fee due as a result of this paper, not covered by an enclosed check, may be charged on Deposit Acct. No. 08-1634.

Attorney Docket No. HERR 18.313

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<u>CE</u>

09/762283

Inventor:

Rosa PEREZ GOMARIZ, et al.

Serial No.:

09/762,283

Filed:

February 5, 2001

Title:

METHOD FOR TREATING ENDOTOXIC SHOCK

AND INFLAMMATORY AND AUTOIMMUNE

**DISEASES IN MAMMALS** 

Examiner:

Art Unit:

April 13, 2001

Assistant Commissioner for Patents Washington, D.C. 20231

## INFORMATION DISCLOSURE STATEMENT

SIR:

In order to comply with discretionary rules 37 CFR §§1.97 and 1.98, attached hereto is a copy of Form PTO-1449 and copies of the documents listed thereon. These documents contain information which the Examiner may consider to be important in deciding whether to issue a patent in the instant application.

As this Statement is being filed prior to issuance of a first Office Action, no fee is due.

As one document is written in a language other than English, an English language abstract is annexed hereto explaining the relevancy in accordance with 37 CFR §1.98(a)(3).

The present Information Disclosure Statement is being submitted in compliance with 37 CFR §1.56 as an Examiner might consider any cited document important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104 (a) and 1.106 (b), and in the course of such search will review for relevance every document cited on the attached form even if not initialed.

Early and favorable consideration is respectfully solicited.

Any fee due with this paper, not fully covered by an enclosed check, may be charged on Deposit Account 08-1634.

Respectfully submitted,

Aaron B. Karas Reg. No. 18,923

HELFGOTT & KARAS, P.C. EMPIRE STATE BUILDING 60TH FLOOR NEW YORK, NEW YORK 10118 (212) 643-5000

DOCKET NO. HERR 18.313

Please type a plus sign  $(+) \rightarrow +$ 

Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

1449/PTO

U.S. Department of Commerce Patent and Trademark Office

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

.0. 20	
Application No.	: 09/762,283
Filing Date	: February 5, 2001
First Named Inventor	: R.P. Gomariz, et al.
Group Art Unit	:
Examiner Name	:

Attorney Docket No. : HERR 18.313

Sheet 1 of

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document	Kind Code if known <sup>2</sup>	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns Lines Where Relevant Passages or Relevant Figures Appear

	T 01.			FENT DOCUMENTS  Name of Patentee or Applicant	Date of	Pages, Columns
Examiner Initials	Cite No.	Foreign Patent Document Office <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Country	of Cited Document	Publication of Cited Document MM-DD-YYYY	Lines Where Relevant Passages or Relevant Figures Appear
		WO 99/53944	WIPO		10/28/1999	

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), data, page(s), volume-issue number(s), publisher, country, where published, source.  Advances in Neuroimmunology, Vol. 6, pp. 61-74, 1996, Elsevier	Applicant check here if English language translation attachedT
Advances in Neuroimmunology, Vol. 6, pp. 61-74, 1996, Elsevier	
Science, Ltd., D. Ganea, "Regulatory effects of vasoactive intestinal peptide on cytokine production in central and peripheral lymphoid organs.	

Examiner	Date	
Signature	Considered	

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw a line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.1<sup>6</sup> if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take .2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it displays a valid OMB control number. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.